Cellectar Biosciences, Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. Filed August 10, 2020. Cellectar is a clinical-stage cancer biopharmaceutical company developing phospholipid drug conjugates (PDCs). It reported no product revenue; operations are funded primarily through securities offerings.
Financial performance
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development | $2.465 million | $1.810 million | $5.082 million | $4.118 million |
| General and administrative | $1.157 million | $1.391 million | $2.499 million | $2.712 million |
| Total operating costs and loss from operations | $3.622 million | $3.200 million | $7.581 million | $6.830 million |
| Net loss | $3.612 million | $3.188 million | $7.570 million | $6.809 million |
| Loss per share, basic and diluted | $0.26 | $0.46 | $0.65 | $1.15 |
As a pre-commercial company, it has no meaningful revenue or gross-margin measure; operating margins are not meaningful. Net loss increased year over year, while loss per share decreased, primarily reflecting a substantially larger weighted-average share count. Q2 R&D rose 36%, driven by clinical project and personnel-related costs; manufacturing costs declined. Six-month R&D rose 23%. G&A fell 17% for Q2 and 8% for the six-month period, primarily due to lower stock-based compensation.
Cash, liquidity, and capital
- Cash and cash equivalents were $22.45 million at June 30, 2020, versus $10.61 million at December 31, 2019. Current assets were $23.04 million and current liabilities $3.32 million.
- For the six months, operating cash use was $6.56 million, investing cash use was $45,000, and financing cash provided was $18.44 million. Net cash increased $11.84 million.
- The June public offering generated $20.0 million gross and approximately $18.3 million net proceeds. It included common shares, pre-funded warrants, and Series H warrants. Common shares outstanding increased from 9.39 million at year-end to 25.47 million at June 30; 19.28 million warrants were outstanding at quarter-end.
- Long-term liabilities included a $184,000 Paycheck Protection Program (PPP) loan and lease liabilities; no other material borrowing was reported. The PPP loan bears 1% interest, with potential forgiveness subject to program conditions.
- Accumulated deficit was $119.25 million. Management said cash should fund basic budgeted operations for at least 12 months from filing, but additional funding is needed to execute plans beyond that period. The company expects continuing operating losses and has no assurance of obtaining further financing.
Business developments, outlook, and risks
- Lead candidate CLR 131 was being evaluated in Phase 2 for relapsed/refractory B-cell malignancies and in Phase 1 for pediatric solid tumors and lymphoma. The filing describes previously reported CLOVER-1 activity and safety findings; these are clinical results, not established product efficacy.
- COVID-19 had not yet caused significant overall operational impact, and clinical-trial enrollment continued. However, the pandemic could hinder patient recruitment, CLR 131 supply, financing, and timelines. A CLR 131 head-and-neck cancer trial was suspended due to COVID-19 and subsequently reopened for enrollment.
- The company received European Medicines Agency SME status in June, which provides regulatory fee reductions and other support. It also reported multiple partnered and preclinical PDC programs.
- Management reported effective disclosure controls and no significant changes in internal control over financial reporting. The filing lists no material legal proceedings.
- Management’s 12-month liquidity assessment contrasts with the prior auditor’s going-concern explanatory paragraph for 2019. Continued losses, capital needs, potential dilution, clinical and regulatory uncertainty, supply dependence, and COVID-19 disruption remain significant risks.
Key facts for investors to verify
- Whether cash burn and updated trial spending remain consistent with the stated minimum 12-month runway, and when additional capital may be required.
- The effect of the June financing and outstanding warrants on fully diluted share count and future dilution.
- Current CLR 131 trial enrollment, timing, data maturity, and whether COVID-19 or supply constraints have changed study timelines.
- PPP loan forgiveness status and any conditions or repayment obligations.
- Whether subsequent clinical, regulatory, or financing developments alter the filing’s outlook and risk disclosures.